FDA
-
-
-
-
-
-
-
TScan reports positive Phase 1 trial data for blood cancer treatment
-
-
-
-
-
-
-
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
TScan Therapeutics (TCRX) Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
-
-
-
-
-
-
-
TScan Therapeutics, Inc (TCRX) Announces FDA Clearance of Three Investigational NDAs for Treatment of Solid Tumors
-
-
-
-
-
-
-
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
-
323,712 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

